Clik here to view.
Nohla Therapeutics Launches with Major US Cancer Research Institute Deal,...
SEATTLE Nohla Therapeutics Inc. (Nohla), a new cellular therapies start-up based in Seattle, Washington, is pleased to announce the signing of an exclusive licensing and collaboration agreement with...
View ArticleClik here to view.
Frontline BioVentures to Form Strategic Partnership with Sinopharm Group Co.,...
SHANGHAI Frontline BioVentures, a premier healthcare venture capital firm based in China, announced today that it has led a Series A round of financing for Sino Health, an invested company of...
View ArticleClik here to view.
Samsung Bioepis’ RENFLEXIS® Infliximab Biosimilar Receives Regulatory...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® – a biosimilar version of Remicade® (infliximab), also known as...
View ArticleClik here to view.
Promega NanoBiT Complementation Assay Named a Top 10 Innovation
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 MADISON, Wis. The Scientist named Promega NanoBiT™ (NanoLuc® Binary Technology) Assay as a Top 10 Innovation for 2015. This is the third...
View ArticleClik here to view.
Clik here to view.
武田报告ADCETRIS® (Brentuximab Vedotin)的5年总生存数据，结果显示复发/难治霍奇金淋巴瘤可持久缓解
佛罗里达州奥兰多 (美国商业资讯) — 武田药品工业株式会社(TSE:4502)发布了 brentuximab vedotin单药治疗自体干细胞移植(ASCT)后复发或难治霍奇金淋巴瘤枢纽性2期研究的治疗后随访数据。数据显示，ADCETRIS治疗患者的5年总生存(OS)率估值为41% (95% CI: 31%, 51%)；中位OS期为40.5个月（95% CI: 28.7, 61.9...
View ArticleClik here to view.
Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and...
OSAKA, Japan & CHICAGO Takeda Pharmaceutical Company Limited (TOKYO:4502) and Cour Pharmaceutical Development Company, Inc. today announced a partnership to research and develop novel immune...
View ArticleClik here to view.
武田薬品とCour社のセリアック病等の消化器疾患に対する治療薬の共同研究開発契約について
大阪 & シカゴ （ビジネスワイヤ） — 武田薬品（本社：大阪市中央区、以下「武田薬品」）とCour Pharmaceuticals Development Company,...
View ArticleClik here to view.
Arcadia Biosciences and BGI to Create Global Non-GM Genetic Resource for Rice
DAVIS, Calif. & SHENZHEN, China Arcadia Biosciences, Inc. (Nasdaq:RKDA), an agricultural technology company, and BGI, the world’s largest genomics organization, announced a collaboration to...
View ArticleClik here to view.
华大基因与美国Arcadia Biosciences合作共建全球水稻非转基因遗传资源数据库
加州戴维斯，中国深圳 (美国商业资讯)–全球最大的基因组学研发机构华大基因与美国农业技术公司Arcadia Biosciences(NASDAQ: RKDA)宣布合作共建水稻遗传资源数据库，以推进世界粮食作物的研究和发展。 Smart News Releases（智能新闻稿）是一个多媒体平台。在此处查看完整新闻稿：...
View ArticleClik here to view.
武田が多発性骨髄腫の治療のために最近承認された週1回経口プロテアソーム阻害薬として初にして唯一のNINLARO®（イキサゾミブ）の第3相TOURMALIN...
米フロリダ州オーランド （ビジネスワイヤ） —...
View ArticleClik here to view.
武田呈报近期核准用于多发性骨髓瘤的首个也是唯一的每周一次口服蛋白酶体抑制剂NINLARO® (ixazomib)的3期TOURMALINE-MM1研究数据
佛罗里达州奥兰多 (美国商业资讯) — 武田药品工业株式会社(TSE:4502)今天在美国血液学会(ASH)第57届年会和展览上发布了TOURMALINE-MM1试验的结果，该结果显示，NINLARO®...
View ArticleClik here to view.
武田与Cour合作开发治疗腹腔疾病及其他胃肠道疾病的新型疗法
日本大阪和芝加哥 (美国商业资讯) — 武田药品工业株式会社(TOKYO:4502)和Cour Pharmaceutical Development Company,...
View ArticleClik here to view.
武田薬品、アドセトリス（ブレンツキシマブ・ベドチン）の5年全生存率データが再発性／難治性ホジキンリンパ腫患者で長期寛解を示すと報告
米フロリダ州オーランド （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:4502）は、自家幹細胞移植（ASCT)後の再発性／難治性ホジキンリンパ腫の治療を目的としたブレンツキシマブ・ベドチン単剤療法のピボタル第2相試験から得られた治療後フォローアップのデータを発表しました。データは、アドセトリスによる治療を受けた患者の推定5年全生存率（OS）が41パーセント（95% CI:...
View ArticleClik here to view.
Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in...
HOUSTON & TOKYO Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM, “Bellicum”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that Agensys, Inc. (“Agensys”), an affiliate of...
View ArticleClik here to view.
NINLARO® (ixazomib) Now Available for Patients
CAMBRIDGE, Mass. & OSAKA, Japan NINLARO® (ixazomib) capsules, the first and only oral proteasome inhibitor, are now available in the United States. NINLARO is indicated in combination with...
View ArticleClik here to view.
昆泰推出整合资产开发规划的成套服务
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 北卡罗莱纳州研究三角园区 (美国商业资讯)–世界最大的生物制药服务提供商昆泰今天宣布推出综合资产开发规划(IADP)服务。这套新服务结合开发策略、法规策略、市场进入和患者接触及商业专项技能与深度治疗知识、简化的战略规划流程、数据分析和建模，以交付综合资产开发规划。...
View ArticleClik here to view.
Chugai’s ALK Inhibitor “Alecensa®” Accelerated Approval in Three Months after...
TOKYO Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Genentech Inc., a member of the Roche Group, obtained approval from the U.S. Food and Drug Administration (FDA), for the...
View ArticleClik here to view.
Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and...
CAMBRIDGE, Mass. & OSAKA, Japan Akebia Therapeutics, Inc. (NASDAQ:AKBA), and Mitsubishi Tanabe Pharma Corporation (TSE:4508) (MTPC) announced today that they have entered into a development and...
View ArticleClik here to view.
クインタイルズが資産開発計画を統合するための一連のサービスの提供を開始
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 米ノースカロライナ州リサーチ・トライアングル・パーク （ビジネスワイヤ） —...
View Article